(E/Z)-Necrosulfonamide
Product Sizes
10 mg
£ POA
HY-100573A-10MG
5 mg
£ POA
HY-100573A-5MG
50 mg
£ POA
HY-100573A-50MG
25 mg
£ POA
HY-100573A-25MG
100 mg
£ POA
HY-100573A-100MG
10mM/1mL
£ POA
HY-100573A-10MM
About this Product
- SKU:
- HY-100573A
- CAS Number:
- 432531-71-0
- Extra Details:
- (E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor; capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals; but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis; activate the Nrf2 pathway and the downstream antioxidant enzymes; and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease); tissue damage and ischemia-reperfusion injury; inflammatory bowel disease; osteoarthritis and fracture repair; and hair loss by regulating two important programmed necrosis pathways.
- Molecular Weight:
- 461.47
- Purity:
- 98.03
- References:
- [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Sun L, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1-2):213-227.
- Research Area:
- Endocrinology; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- MAPK/ERK Pathway
